iBio, Inc.

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
iBio is a global leader in plant-based biologics manufacturing. Its FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services via its 130,000 square foot facility in Bryan, Texas. iBio’s FastGlycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing proprietary products which include IBIO-100 for the treatment of fibrotic diseases and IBIO-200, a COVID-19 vaccine.
Ticker:
IBIO
Exchange:
NYSE
Company Type:
Not Provided
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
IBIO-100
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
CEO
iBio, Inc.